durobinet schreef op 30 november 2018 12:39:
With the three drugs that Gilead has in its pipeline, the company could cover all stages of the disease using various combinations, and one of the drugs has shown an ability to reverse the thrombosis that can occur in NASH.
Spray speculated that the next CEO (GILD) will also be expected to find potential new acquisitions that will kick-start revenues before these drugs reach the end of clinical development.
“If they are looking for a new CEO they may want to spend money late stage assets so they can boost revenue immediately,” said Spray.
pharmaphorum.com/news/gilead-needs-de...Is de CEO GLPG een deal maker? En kan hij als CEO GILD van GLPG de grootste pharma business van Europa maken? Denk het niet.
Nee, een overname ligt meer voor de hand.